Constipation : Affects approximately 324% of patients depending on the specific medication and dose, likely due to significantly slowed gastrointestinal transit time
It is priming your receptor systems, establishing tolerance, and laying the foundation for higher doses to work effectively without overwhelming your body
[] Furthermore, the GIPRs are also found in adipocytes, myeloid cells, endothelial of the heart, blood vessels, pituitary, adrenal cortex, cerebral cortex, hippocampus, olfactory bulb, hypothalamus, and hindbrain
Combining with DPP-4 inhibitors is generally not recommended, as both drug classes work on the incretin system Adding basal insulin for those with more significant hyperglycaemia, which can be used alongside GLP-1 medications (with careful monitoring for hypoglycaemia) Switching to insulin therapy entirely may be necessary for those with advanced beta cell failure For weight management , when GLP-1 medications don't produce adequate weight loss, alternatives include: Orlistat , a lipase inhibitor that reduces fat absorption, though weight loss is typically modest (2-3 kg on average) Naltrexone-bupropion (Mysimba), which works on appetite centres through different pathways
The 2 major incretins found in the body are gastric-inhibitory-polypeptide (GIP) and glucagon-like-peptide-1 (GLP-1) [2]
